Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Year: 2013
Type: article
Abstract: Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.
Source: Leukemia Research
Institutions: IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, South Australia Pathology, Centre for Cancer Biology, The University of Adelaide, Hôpital Lyon Sud, University of Michigan, U-M Rogel Cancer Center, University of Utah, Huntsman Cancer Institute, Heidelberg University, University Medical Centre Mannheim, Fred Hutch Cancer Center, University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,910
OpenAlex ID: W2070375208